Last reviewed · How we verify
S-1 + Cisplatin (arm A)
S-1 is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase and other enzymes in nucleotide synthesis, while cisplatin is a platinum-based alkylating agent that cross-links DNA, together producing synergistic cytotoxic effects against cancer cells.
S-1 is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase and other enzymes in nucleotide synthesis, while cisplatin is a platinum-based alkylating agent that cross-links DNA, together producing synergistic cytotoxic effects against cancer cells. Used for Gastric cancer, Gastroesophageal junction cancer, Esophageal cancer.
At a glance
| Generic name | S-1 + Cisplatin (arm A) |
|---|---|
| Sponsor | Taiho Pharmaceutical Co., Ltd. |
| Drug class | Fluoropyrimidine + platinum-based chemotherapy combination |
| Target | Thymidylate synthase (S-1); DNA (cisplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
S-1 (tegafur/gimeracil/oteracil potassium) is converted to fluorouracil in tumor tissue and inhibits thymidylate synthase, disrupting DNA synthesis. Cisplatin forms DNA adducts and cross-links, preventing DNA replication and transcription. The combination exploits complementary mechanisms of action to enhance cell death in rapidly dividing cancer cells.
Approved indications
- Gastric cancer
- Gastroesophageal junction cancer
- Esophageal cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea/vomiting
- Diarrhea
- Stomatitis
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
Key clinical trials
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (PHASE3)
- Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma (PHASE2)
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma (PHASE2)
- Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (PHASE2)
- Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial (PHASE3)
- A Safety and Efficacy Study in Patients With Gastric Cancer (PHASE3)
- Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-1 + Cisplatin (arm A) CI brief — competitive landscape report
- S-1 + Cisplatin (arm A) updates RSS · CI watch RSS
- Taiho Pharmaceutical Co., Ltd. portfolio CI